TABLE 1.
Baseline demographics and clinical characteristicsa
| Characteristic | Low-dose cohort (n = 11)b | High-dose cohort (n = 12)c |
|---|---|---|
| Age (mean [range]) (yr) | 47.8 (32–67) | 48.4 (24–62) |
| Sex (no. [%]) | ||
| Men | 7 (63.6) | 10 (83.3) |
| Women | 4 (36.4) | 2 (16.7) |
| Caucasian (no. [%]) | 11 (100.0) | 12 (100.0) |
| Wt (mean [range]) (kg) | 74.2 (54.9–101.4) | 86.6 (56.2–117.0) |
| Ht (mean [range]) (cm) | 174.6 (160–186) | 178.9 (164–189) |
| BMI (mean [range]) (kg/m2)d | 24.2 (18.3–31.3) | 26.9 (20.4–36.1) |
a
For the safety population (received ≥1 dose of study medication).
b
Isavuconazole administered as a 200-mg once-daily maintenance regimen.
c
Isavuconazole administered as a 400-mg once-daily maintenance regimen.
d
BMI, body mass index.